Whey versus egg white protein: which causes less ammonia rise in alcohol-related decompensated cirrhosis
Official title: Effect of Whey Protein Versus Egg Albumen Protein Challenge on Blood Ammonia Level in Patients of Decompensated Ethanol Related Cirrhosis.
Run by Institute of Liver and Biliary Sciences, India · NCT07299110 · Data updated 2026-11-12
This trial will test whether 30 g of whey protein or 30 g of egg white protein causes a smaller rise in blood ammonia and affects minimal hepatic encephalopathy in adults with decompensated alcohol-related cirrhosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 70 Years |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Institute of Liver and Biliary Sciences, India Academic / other |
| Locations | 1 site (New Delhi) |
| Status | Recruiting |
| Started | December 12, 2025 |
| Main results expected | December 31, 2025 |
| Study ends | December 31, 2025 |
| Registry record updated | December 31, 2025 |
| Trial ID | NCT07299110 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–70 with decompensated ethanol-related cirrhosis who can give informed consent, have no history of overt hepatic encephalopathy, are not on rifaximin or lactulose, and have no egg or dairy allergy.
✕Probably not a fit
Patients with overt hepatic encephalopathy, recent GI bleeding or active infection, significant renal impairment, hepatocellular carcinoma, TIPS, current HE medications, or egg/dairy allergy are unlikely to be eligible or to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a crossover pilot in 50 adults with decompensated ethanol-related cirrhosis without overt hepatic encephalopathy. Each participant will receive two standardized 30 g protein challenges—one whey and one egg albumen—24 hours apart, with venous ammonia measured before and at set times after ingestion and minimal hepatic encephalopathy (MHE) testing performed. Whey is rich in branched-chain amino acids and is rapidly absorbed, while egg albumen digests more slowly and is higher in aromatic amino acids, which may increase ammoniagenesis. The crossover design lets each person act as their own control to directly compare postprandial ammonia responses to the two proteins.
Why it matters
Potential benefit: If successful, results could help patients and clinicians choose protein supplements that produce less ammonia and reduce the risk or severity of minimal hepatic encephalopathy.
How similar studies have gone: Prior work indicates BCAA-rich proteins like whey may be less ammoniagenic and can help cognitive symptoms in cirrhosis, but direct head-to-head crossover protein-challenge data are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Known or newly diagnosed (clinical, imaging) case of decompensated ethanol related cirrhosis patients. 2. Age (18-70 years). 3. Informed consent to participate in the study. Exclusion Criteria: 1. History of overt HE (West Haven grade II or more). 2. Last Intake \<1.5 months. 3. CKD (creatinine \>1.5 mg/dL), active infection, GI bleeding in past 2 weeks. 4. Severe anaemia (Hb \<7 g/dL) or hypoalbuminemia (\<2.0 g/dL). 5. Known egg or dairy allergy. 6. Those on sedatives, antidepressant or anti-psychiatric medication. 7. Unable to understand the language or instructions. 8. Hepatocellular Carcinoma. 9. TIPS. 10. Receiving rifaximin or lactulose. 11. Diarrhea, SIBO or malabsorptive syndrome.
Where it's running
-
Institiute of liver and biliary sciences
New Delhi, India Recruiting
Study contacts
- Study coordinator: Dr Ishank Johri, MD
- Email: ishankjohri@gmail.com
- Phone: 01146300000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Developing and validating a formula to detect major kidney events in people with decompensated cirrhosis and ascites
This observational study aims to test a new equation that helps identify major adverse kidney events in adults with decompensated cirrhosis and ascites who have stable kidney function.
-
Magnetic Resonance Cholangiopancreatography to help living liver donors and their recipients
This study tests whether preoperative MRCP imaging can help select living liver donors and reduce biliary complications in recipients.
-
Genetic factors in graft fatty liver after living-donor liver transplant
This study will see if donor and recipient genetic variants, especially PNPLA3 and MBOAT7, are linked to fat buildup in the transplanted liver among adults who had living-donor liver transplants for MAFLD-related cirrhosis.
-
Bone mineral changes after living-donor liver transplant
Bone density scans will be used to see how bone mineral density changes in adults with chronic liver disease who receive a living-donor liver transplant.
-
How often staging laparoscopy finds hidden spread in liver, pancreas, and bile duct cancers
This project will test whether staging laparoscopy still finds hidden metastases in people with suspected hepatopancreatobiliary cancers given modern imaging like CT, MRI, EUS, and PET-CT.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.